You just read:

Interim Data From Phase 2 Trial of AC220 Monotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia With FLT3-ITD Activating Mutations

News provided by

Astellas Pharma Inc.

13 Jun, 2011, 13:30 BST